Burkholderia infections are caused by Burkholderia
cepacia. It is a gram negative bacillus found in aquatic
environment. It is a low virulent bacteria and is a frequent
colonizer of fluids used in the hospitals such as IV fluid,
irrigation solution etc. B. Cepacia can cause health
problems to some people such as patients suffering from weakened
immune system or chronic lung diseases. Burkholderia infection
symptom can vary widely in people, ranging from no symptoms to
serious respiratory infection. Based on recent genomic subtyping
techniques, Burkholderia infection can be transmitted from person to
person. Patients with lung disease such as asthma, CFTR, and COPD are
at high risk of suffering from Burkholderia infection. Burkholderia
cepacia is resistant to multiple antibiotic such as aminoglycosides,
antipseudomonal third-generation cephalosporins and antipseudomonal
penicillins.
Fill the form for an exclusive sample of this
report @
https://www.coherentmarketinsights.com/insight/request-sample/153
Global Burkholderia Infections Market
Taxonomy
On the basis of drug type, the global market is
classified as follows:
-
Trimethoprim
-
Sulfamethoxazole
-
Trimethoprim and sulfamethoxazole
-
Meropenem
-
Minocycline
-
Cefepime
-
Tigecycline
-
Fluoroquinolones
-
Others
On the basis of distribution channel, the global
market is classified as follows:
-
Hospital Pharmacies
-
Retail Pharmacies and Drug Store
-
E-commerce
-
Others
Prevalent Scenarios in Burkholderia
infections Market
Increasing prevalence of lung diseases is expected
to fuel growth of the Burkholderia infections market. The exact cause
for asthma, cystic fibrosis is unknown, though the risk factors can
be transferred generation from generation. As per the report of
British Lung Foundation, in 2011, an estimated 1.2 million people are
living with chronic obstructive pulmonary disease (COPD) and has
grown by 27% in the last decade in the U.K. According to the U.S.
Cystic Fibrosis Foundation, Europe accounted for the highest number
of reported cases of cystic fibrosis in 2012. The growing cases of
COPD, asthma and other lung diseases create high risk of burkholderia
infection creating an opportunity for manufacturers. Burkholderia
infections also cause complications such as soft tissue infections,
urinary tract infection and surgical wound infections. It creates an
opportunity for the manufacturers to focus on overall treatment. The
increasing outbreaks of burkholderia infection has created focus
towards the need for proper treatment procedure. Many organization
and government policies have included burkholderia infection as one
of the severe infections spread from healthcare facilities.
Transmission of B. Cepacia from contaminated medicines and
medical devices. In 2005, CDC notified several states cluster of
pneumonia and other infection caused by B. Cepacia associated
with contaminated mouthwash. In October, 2016, Nurse Assist Inc,
recalled its normal saline flush IV syringes due to Burkholderia
Cepacia bloodstream infection. FDA identified this as Class I
recall, one of the most serious types of recall which may cause
serious injuries or death. In 2004, Burkholderia Cepacia was
linked to nosocomial infection among Intensive Care Unit patient and
was associated with exposure to sublingual probes. The growing
concerns related to contaminated medicines and medical devices are
expected to create opportunity for product manufacturers in the
burkholderia infections market. The effect of B. cepacia on people
varies person to person which leaves the infection with no specific
treatment. The unavailability of proper treatment creates hindrance
to the overall market. North America is expected to account for
maximum share of the global burkholderia infections market, owing to
the better diagnostic facilities, increasing awareness and government
initiative for early diagnosis and treatment of burkholderia
infection. Europe is expected to be the second most lucrative
burkholderia infections market.
Request to view table of content @
https://www.coherentmarketinsights.com/ongoing-insight/toc/153
Burkholderia Infections Market is Highly
Fragmented
The market is highly fragmented due to the
presence of many emerging players. Major players involved in the
burkholderia infections market includes Novabiotics Ltd, iQur Ltd,
Aridis Pharmaceuticals LLC, NanoBio Corporation, SUN pharma and
others.
About Us:
Coherent Market Insights is a prominent market
research and consulting firm offering action-ready syndicated
research reports, custom market analysis, consulting services, and
competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
No comments:
Post a Comment